Four Weeks of Treatment With Rifaximin Fails to Significantly Alter Microbial Diversity in Rectal Samples of HIV-Infected Immune Non-Responders (ACTG A5286) Which May be Attributed to Rectal Swab Use

Four Weeks of Treatment With Rifaximin Fails to Significantly Alter Microbial Diversity in Rectal Samples of HIV-Infected Immune Non-Responders (ACTG A5286) Which May be Attributed to Rectal Swab Use

Introduction: HIV-infected individuals have evidence of intestinal microbial translocation which is associated with immune activation and unfavorable clinical outcomes. Rifaximin, a non-absorbable antibiotic which reduces microbial translocation in other disease states, was shown to have a marginal...

Full description

Bibliographic Details
Main Authors: Brett B. Williams, Stefan J. Green, Ronald J. Bosch, Ellen S. Chan, Jeffrey M. Jacobson, David M. Margolis, Phillip Engen, Alan L. Landay, Cara C. Wilson
Format: Article
Language:English
Published: Case Western Reserve University 2019-09-01
Series:Pathogens and Immunity
Subjects:
HIV
microbiome
immune activation
microbial translocation
rifaximin
Online Access:https://paijournal.com/index.php/paijournal/article/view/290

Internet

https://paijournal.com/index.php/paijournal/article/view/290

Similar Items